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Background. The possible association between inflammatory
processes and other outcome measures in ESRD patients led us to
measure the blood C-reactive protein (CRP) concentration in a
large sample of hemodialysis patients, and to evaluate its statisti-
cal relationship with other common laboratory measures and
patient survival. This was performed in a prospective, observa-
tional analysis with mortality as the principal outcome measure.
Methods. One thousand fifty-four routine blood samples, col-
lected from as many patients during June and July 1995 (one
sample per patient), were randomly selected for measurement of
CRP, prealbumin, and other routine laboratory measures. Six
months after the initial blood tests, patient survival was deter-
mined. Logistic regression analysis was the primary statistical tool
used to evaluate laboratory associations with odds of death.
Bivariate regression and correlation analyses were performed
using all available data.
Results. The distribution of CRP values was skewed; approxi-
mately 35% of the values exceeded the upper limit of the
laboratory’s reference range. Serum albumin and prealbumin
concentrations both correlated with the serum creatinine concen-
tration (r 5 0.378 and r 5 0.347, respectively; P’s , 0.001), and
were inversely associated with the CRP (r 5 20.254 and r 5
20.354, respectively; P’s ,0.001). CRP was also inversely associ-
ated with blood hemoglobin concentrations (r 5 20.235; P ,
0.001). Using multiple regression analysis to further explore these
relationships, the serum creatinine concentration was inversely
associated with CRP (r 5 20.140; P , 0.001). However, after
adjustment for the linkage of the serum creatinine with the serum
albumin concentration (r 5 20.378; P , 0.001), no relationship
with creatinine was observed. Before and after adjustment for
serum albumin and prealbumin concentration, the ferritin con-
centration correlated directly with CRP (r 5 0.148; P , 0.001).
Ferritin was inversely and highly correlated with total iron binding
capacity (r 5 20.516; P , 0.001). Independent associations of
hemoglobin with albumin (t 5 7.16; P , 0.001), prealbumin (t 5
2.39; P 5 0.017), and CRP (t 5 24.27; P , 0.001) were observed.
Also, the dose of erythropoietin was directly associated with the
CRP concentration, before (r 5 0.081, P 5 0.009) and after (t 5
2.03, P 5 0.042) adjustment for the serum albumin and iron
concentrations. CRP correlated directly with neutrophil (r 5
0.318; P , 0.001) and platelet counts (r 5 0.180; P , 0.001), but
was weakly and inversely correlated with the lymphocyte count
(r 5 20.071; P 5 0.04). A logistic regression analysis performed
using the laboratory variables revealed a strong, independent, and
inverse relationships between the serum albumin and creatinine
concentrations, total lymphocyte count, and the odds risk of
death. In this model, no significant relationship was observed
between the odds risk of death and CRP.
Conclusions. The data presented herein suggest that: (1) strong
predictable associations exist among laboratory proxies for mal-
nutrition, anemia, and the acute phase reaction, and (2) the
pathobiology implied by these laboratory abnormalities influence
patients’ mortal risk primarily through depletion of vital body
proteins, not inflammation.
The processes of patient care that effect clinical out-
comes for patients with end-stage renal disease (ESRD)
have undergone increased scrutiny [1]. Because of its
statistical power as a predictor of mortality for peritoneal
and hemodialysis patients, particular attention has been
placed in the area of nutrition, where the serum albumin
concentration is routinely used as a proxy of visceral
protein nutrition [1–13]. Malnutrition is a common finding
among patients with ESRD [1, 2, 6, 7]. Malnutrition of
visceral proteins often occurs during the course of many
chronic diseases, such as chronic renal failure [14], pro-
tracted infections [15], and cancer [16]. The depletion of
vital proteins in such conditions typically exceeds that
observed in protein/caloric starvation alone [17]. There-
fore, it has been suggested that the malnutrition of chronic
diseases is mediated in part by the release of one or more
catabolic and/or anti-anabolic cytokines that are usually
part of the normal effector limb of adaptive immunity. Such
proinflammatory pathways also promote the enhanced
synthesis of acute phase proteins, described as part of the
acute phase reaction [18–21].
The possible inflammatory association between outcome
processes in ESRD patients led us to quantitate the
C-reactive protein concentration (CRP) and obtain other
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common laboratory measures in a large sample of hemo-
dialysis patients. The serum concentration of CRP reflects
the activity of cytokine-mediated acute phase processes
[22–25] and is roughly proportional to the extent of tissue
injury [26]. Furthermore, selected cytokines stimulate the
hepatic production of CRP and apo-ferritin, while inhibit-
ing synthesis of albumin and prealbumin. The data pre-
sented herein suggest that in patients with ESRD: (1)
strong predictable associations exist among laboratory
proxies for malnutrition and the acute phase processes, and
(2) the pathobiology implied by these laboratory abnormal-
ities influences mortal risk in patients primarily through
depletion of vital body proteins.
METHODS
Blood samples from 1,054 patients, that were routinely
sent to LifeChem clinical laboratory (Rockleigh, NJ, USA)
for processing during June and July 1995 (one blood
sample per patient), were randomly selected for measure-
ment of the CRP and prealbumin concentrations. Other
routinely measured laboratory tests were performed only as
ordered by the nephrologists. Because neither the patients
nor their nephrologists were aware of their participation in
the observational analysis, routine laboratory tests were
ordered based on physician preference and clinical indica-
tions alone. Because of variability in nephrologists’ practice
styles and patients’ case mix, the individual tests performed
differed from patient to patient. The routine laboratory
tests were categorized as “primary” or “extended.” Primary
laboratory tests were those that had been performed on the
largest number of patients; extended laboratory tests were
performed on a smaller number of subjects, but provided
the greatest number of tests for statistical analysis (Table
1). Both categories of tests composed the initial data set.
Six months after the initial blood sampling (January and
February 1996), the patients were classified as alive on
dialysis or dead. A total of 988 patients lived for six months
after blood sampling or died during that interval. The
remaining 66 patients were censored from further analysis
because of renal transplantation (N 5 26), transfer to other
facilities (N 5 31), or miscellaneous reasons (N 5 9), such
as recovery of renal function or loss to follow up. Eight
hundred forty-five of these 988 patients had complete
primary laboratory data; 570 of these 988 patients had
complete primary and extended laboratory data.
The patients’ survival status, and their individual demo-
graphic characteristics extracted from Fresenius Medical
Care’s Patient Statistical Profile System (PSP), were
merged with the initial data set to create the final data set.
The PSP contains information for the individual patient’s
date of birth, gender, etiology of renal disease, and censor
date, if applicable [2, 4, 6]. The final data set was used to
evaluate the statistical association of the laboratory test
Table 1. Distribution of data elementsa




Albumin gm/dl 1051 3.89 0.43 3.5–5.2
Alkaline phosphatase U/liter 1051 140.53 194.46 39–117
CO2 mEq/liter 1051 20.47 3.30 23–29
Creatinine mg/dl 1051 10.80 3.50 0.6–1.6
C-reactive protein mg/dl 1054 1.29 2.10 ,0.8
Ferritin ng/ml 1042 322.84 430.05 5–179
Hemoglobin gm/dl 946 10.16 1.38 11.4–17.0
Iron mcg/dl 1045 53.51 30.57 37–145
Lactate dehydrogenase U/liter 1051 210.35 59.04 118–273
Phosphorus mg/dl 1051 6.00 1.90 2.7–4.5
Potassium mEq/liter 1051 4.84 0.81 3.5–5.3
Pre-albumin mg/dl 1053 29.16 7.04 18.0–33.8
Total iron binding capacity mcg/dl 1015 216.29 49.98 259–388
Iron binding capacity saturation % 1015 25.22 13.60 20–55
Extended laboratory tests
BUN mg/dl 1051 67.26 18.84 6–19
ALT U/liter 1051 18.26 14.21 0–37
AST U/liter 869 16.47 21.4 0–40
Lymphocyte count 103/ml 870 1.37 0.62 0.9–5.2
Neutrophil count 103/ml 870 4.90 2.32 1.9–8.0
Platelet count 103/ml 869 221.94 84.66 150–450
Reticulocyte count % 968 1.72 0.87 0.3–2.1
Other laboratory variables
Age years 1054 59.33 15.49 NA
MCHC g/dl 945 30.91 1.32 33–37
MCV mcm3 945 95.24 7.87 80–99
URR % 973 67.37 8.52 $65
a N is number of patients on whom the test was performed; SD is standard deviation. Nine hundred four patients had complete primary laboratory
tests. Six hundred ten patients had complete primary and extended tests.
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results and other variables with the patients’ mortal out-
comes. In the final data set, logistic regression analysis was
the primary statistical tool used to evaluate associations
with odds of death [27]. A forward stepwise regression
process was used for two core analyses, which included
patient ages, gender, diabetic status, and either the primary
laboratory variables or both the primary and extended
laboratory variables. The Null Hypothesis of “no associa-
tion” was rejected if P # 0.05, considered indeterminate if
P . 0.05 and # 0.10, and accepted if P . 0.10. Bivariate
regression and correlation analyses were performed using
all available data.
To evaluate for possible analytical bias from the original
database and/or the statistical constraints of the logistic
regression analysis, three supplementary data analyses were
performed (“sensitivity analysis”). Arguably, error or bias
in the original data analysis may be introduced by: (1)
different test ordering practices of the nephrologists, (2)
volatility of test results that may not be appreciated by the
use of single laboratory values, rather than to average serial
tests results, and/or (3) selection or statistical bias resulting
from the elimination of censored patients (because of renal
transplantation, transfer to other facilities, or miscella-
neous reasons, such as recovery of renal function or loss to
follow up), as required for a logistic regression analysis.
Firstly, 275 patients did not have an extended laboratory
test measured. So that these patients could be included in
the supplementary analysis, an average value for an indi-
vidual extended laboratory test was calculated from those
available. This value was then substituted as the missing
value for that test among the 275 patients. To evaluate
potential differences in the odds risk of death between
them and the patients with complete laboratory data (610
patients had complete data for both primary and extended
tests), a dummy variable was also created to identify those
patients with substituted data; this was also used in a
logistic regression analysis. Secondly, rather than using a
single, “point in time” value, as in the principal data
analysis, the average laboratory test values were calculated
from up to three months prior to June 1995 and was
substituted. In this circumstance, the single value from the
principal analysis was not included in the average. CRP and
serum prealbumin concentrations were exempted from
these substitutions because no other values were available
for them. Thirdly, we performed two analyses of survival
time using a Cox proportional hazard model instead of the
odds risk of death [28]. Unlike a logistic regression model,
the Cox model permits inclusion of the censored patients,
as well as those who lived or died during the period of
observation.
Different regression models were evaluated by compar-
ing the R-square statistic (R2), resulting from each of
several models. The R2 term reports the proportion of
variability in the dependent variable that is explained by the
independent variable. The trend line, 95% confidence
interval, and 95% prediction interval were calculated from
the models demonstrating the best fit. Unless otherwise
specified, all selected models were linear. For some vari-
ables, especially CRP and ferritin, the distributions of
values were not normal. Normal distributions, without
major discontinuities, were generated for CRP by trans-
forming it using the equation (log10 [11CRP])1⁄2. Ferritin was
transformed to log10 of its concentration. However, both
original and transformed values were used for analysis.
CRP was determined by the rate nelphelometry (Beck-
man Instruments, Inc., Galway, Ireland) [29]. Prealbumin
concentration was determined by immunoprecipitin analy-
sis (Incstar Corporation, Stillwater, MN, USA) [30]. Other
blood chemistry values were determined on Hitachi Model
736-50 and 747-200 analyzers using conventional methods
and reagents (Boehringer Mannheim Corp., Indianapolis,
IN, USA), and the serum albumin concentration was
determined on that device by the bromocrysal green
method. Hematological values were determined using stan-
dard laboratory equipment, methods and reagents (H-
System; Bayer diagnostics, Terrytown, NY, USA). The urea
reduction ratio (URR) was calculated as the difference
between the predialysis and postdialysis blood urea nitro-
gen (BUN) concentration divided by the predialysis value
and multiplying the quotient by 100 [2].
RESULTS
Patient demographics and laboratory test values
Over one half (54.8%) of the patients were white, 41.1%
were African American, and 4.1% were of other races.
Over one third (35.9%) had diabetes mellitus as a comor-
bid condition. The gender distribution was 47.5% female.
Therefore, this patient subset resembled that of the prev-
alent American ESRD population [31], except for a modest
over-representation of African Americans that may have
augmented patient survival based on prior observational
outcome analyses [32]. The distributions of primary and
extended test values are shown in Table 1.
The serum albumin concentrations for this patient group
was 3.9 6 0.4 g/dl (mean 6 SD). The mean serum creatinine
concentration was 10.8 6 3.5 mg/dl. Most patients were
moderately to severely anemic. One half had a hemoglobin
concentration # 10.9 g/dl with lower quartile # 9.4 g/dl
(Table 1). Approximately 84% of the patients (83.7%)
received recombinant human erythropoietin (rhEPO), pre-
dominantly intravenously (.95%). Patients not receiving
rhEPO had higher hemoglobin concentration than patients
receiving the hormone (10.8 6 1.8 and 10.1 6 1.6 g/dl,
respectively; mean 6 SD; P , 0.001), and the relationship
between hemoglobin concentration and rhEPO dose was
inverse (r 5 20.213; P , 0.001). Putative laboratory
measures of iron stores [iron, total iron binding capacity
(TIBC), iron binding capacity (IBC) saturation, ferritin]
suggested that iron deficiency was not prevalent. Although
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the total iron binding capacity was low, mean iron concen-
tration was normal. IBC saturation was low normal and the
ferritin concentration was elevated.
The distribution of CRP is shown in Table 1 and Figure
1. The distribution of CRP values was skewed. Approxi-
mately 35% of values from this random patient sample
exceeded the upper limit of the laboratory’s reference
range. The distribution of other data elements is shown in
Table 1.
Bivariate and multivariate relationships
Serum albumin and prealbumin concentrations were
highly correlated (r 5 0.479, P , 0.001), and both corre-
lated with the serum creatinine concentration (r 5 0.378
and r 5 0.347, respectively; P’s ,0.001). Figure 2 illustrates
the relationship of transformed values CRP with serum
albumin concentrations (r 5 20.254; P , 0.001), respec-
tively. Both were linear and inverse throughout the ranges
of observation. The correlation coefficients were of similar
magnitude for transformed and non-transformed CRP
values. CRP was also inversely associated with prealbumin
concentration (r 5 20.354; P , 0.001).
The bivariate associations between selected variables
were examined to more clearly analyze other relationships.
Figure 3 illustrates the relationships of transformed values
of CRP with blood hemoglobin concentrations (r 5
20.235; P , 0.001). CRP was also inversely associated with
IBC (r 5 20.205; P , 0.001). The serum albumin concen-
tration correlated directly with the blood hemoglobin con-
centration (r 5 0.326; P , 0.001; Fig. 4). Even after
adjustment for this interaction, the blood hemoglobin
concentration also directly correlated with the prealbumin
concentration (r 5 0.259; P , 0.001). Although the blood
hemoglobin concentration correlated with the serum cre-
atinine concentration (r 5 0.107; P , 0.001), adjustment
for the serum albumin concentration abolished this rela-
tionship. Lastly, TIBC was also strongly and inversely
correlated with ferritin concentration (rtransformed 5
20.516; P , 0.001). Figure 5 illustrates this relationship.
Multiple regression analysis was used to explore the
relationship between hemoglobin, visceral protein mea-
sures, and CRP. The serum creatinine concentration was
inversely associated with CRP (r 5 20.140; P , 0.001).
However, after adjustment for its association with the
serum albumin concentration (r 5 20.378; P , 0.001), no
relationship with creatinine was observed. Before and after
adjustment for serum albumin and prealbumin concentra-
tion, both transformed and untransformed ferritin concen-
tration were directly correlated with CRP (rtransformed 5
0.148; P , 0.001). Independent associations of hemoglobin
with albumin (t 5 7.16; P , 0.001), prealbumin (t 5 2.39; P 5
0.017), and CRP (t 5 24.27; P , 0.001) were observed, but
not with IBC. Also, the dose of rhEPO was directly correlated
with the CRP concentration, before (r 5 0.081, P 5 0.009)
and after (t 5 2.033, P 5 0.042) adjustment for the serum
albumin and iron concentrations. The dose of rhEPO was not
correlated with prealbumin, creatinine, TIBC, IBC Sat, or
ferritin concentration. Weak inverse associations between
Fig. 1. Box and whisker plot showing the
distribution of transformed C-reactive
protein (CRP) values for 1,054 ESRD
patients. The box defines the upper and
lower quartiles, and the mean is shown by the
cross. The notch indicates the median. Higher
values for CRP are arrayed to the right.
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rhEPO dose and the concentrations of albumin (r 5 20.060,
P 5 0.051) and iron (r 5 20.067, P 5 0.029) were observed.
CRP correlated directly with neutrophil (r 5 0.318; P ,
0.001) and platelet counts (r 5 0.180; P , 0.001), but was
weakly and inversely correlated with the lymphocyte count
(r 5 20.071; P 5 0.04). In turn, the lymphocyte count was
directly correlated with serum albumin (r 5 0.104; P 5
0.002) and prealbumin concentrations (r 5 0.128; P ,
0.001). The neutrophil count was inversely correlated with
the serum albumin (r 5 20.126; P , 0.001) and prealbumin
concentrations (r 5 20.080; P , 0.019).
Principal mortality analysis
Table 2 shows the results of logistic regression analyses
performed using primary plus the extended laboratory
variables, before statistical adjustments for other variables
in the data set. Higher values of albumin, creatinine,
hemoglobin, prealbumin, and TIBC were associated with
lower odds risk (OR) of death, whereas older age and
having diabetes mellitus were associated with higher odds
risk. Higher CRP values were associated with greater death
risk in the analysis of primary laboratory variables but not
Fig. 2. Regression of serum albumin
concentration (g/dl) on transformed C-
reactive protein (r 5 20.254; P < 0.001).
Fig. 3. Regression of blood hemoglobin
concentration (g/dl) on transformed C-reactive
protein (CRP) values (r 5 20.235 and P <
0.001). Transformed values correspond to real
values as follows: 0 5 0; 0.2 5 0.10; 0.4 5 0.45;
0.6 5 1.29; 0.8 5 3.37; 1.0 5 9.00; 1.2 5 26.54.
Upper limits of normal for transformed CRP
values is ,3.37.
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primary and extended laboratory variables. Among the
extended laboratory variables, higher lymphocyte counts
were associated with lower odds risk of death, but higher
neutrophil and platelet counts were associated with higher
odds risk of death.
A multivariable statistical model was evaluated, adjusting
for correlation among the primary laboratory variables
(Table 3). Higher values for the serum albumin and
creatinine concentrations were associated with lower odds
risk of death, whereas higher values of phosphorus were
associated with greater odds risk of death. Females enjoyed
a survival advantage over males. Age, hemoglobin, TIBC,
prealbumin, and CRP were not significantly associated with
the odds risk of death after adjustments for other variables
in the model. Because age was inversely correlated with the
creatinine (r 5 20.483; P , 0.001), the serum creatinine
concentrations likely eliminated age as a statistically signif-
icant variable from the final model. The final logistic model
evaluating the primary plus extended laboratory variables is
summarized in Table 4. Again, the serum concentrations of
albumin, creatinine, and phosphorus appear as the values
most closely associated with odds of death. Even after
Fig. 4. Regression of blood hemoglobin
concentration (g/dl) on serum albumin
concentration (g/dl) (r 5 0.326 and P <
0.001).
Fig. 5. Regression of total iron binding
capacity (TIBC; mg/dl) on transformed ferritin
concentration (r 5 20.52; P 5 0.001).
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adjustment for its correlation with serum albumin concen-
tration, lymphocyte count was also significantly associated
with odds of death. Higher lymphocyte counts were asso-
ciated with more favorable odds,
Sensitivity analyses of mortality
A supplementary analysis was performed that substituted
the average value of the extended laboratory tests for the
missing value of those tests among the 275 patients with
only primary test results. The analysis did not reveal a
significant difference between the patient groups (P 5 0.96
and 0.12 before and after adjustment for other variables in
the model, respectively). The second sensitivity analyses
that substituted the three-month average value of labora-
tory tests for the single value did not reveal meaningful
differences. Again, the analysis of primary laboratory vari-
ables alone revealed the serum albumin (OR 5 0.30; P 5
0.003), creatinine (OR 5 0.85; P 5 0.003), phosphorus
concentrations (OR 5 1.28; P 5 0.003) and gender (OR 5
0.56; P 5 0.052) to be significant predictors of the odds of
death. The potassium (OR 5 1.49; P 5 0.044) and preal-
bumin (OR 5 0.96; P 5 0.052) concentrations were also
significantly associated with death risks. The analysis of
primary plus extended laboratory variables revealed the
serum albumin (OR 5 0.16; P , 0.001), phosphorus
concentrations (OR 5 1.43; P 5 0.002), and lymphocyte
counts (OR 5 0.95; P 5 0.062) as significant predictors of
death risks. However, in this subsidiary analysis, creatinine
was not significant, whereas gender (OR 5 0.50; P 5 0.095)
and age (OR 5 1.03; P 5 0.044) were significant.
Table 2. Logistic regression analysis of demographic and laboratory variables on death
Variable Units
Primary laboratory variables
Primary and extended laboratory
variables
x2 P OR x2 P OR
Age years 6.92 0.008 1.026 3.14 0.077 1.021
Gender Ref 5 male 0.22 NS 0.38 NS
Race Ref 5 nonwhite 2.10 NS 0.53 NS
Diabetes mellitus Ref 5 nondiabetic 2.99 0.084 1.535 3.66 0.055 1.702
Albumin g/dl 25.37 ,0.001 0.229 14.35 ,0.001 0.233
CO2 mEq/liter 0.75 NS 0.57 NS
Creatinine mg/dl 17.31 ,0.001 0.825 11.61 ,.001 0.827
C-reactive protein mg/dl 2.80 0.094 1.096 1.84 NS
Ferritin mg/dl 0.29 NS 0.03 NS
Hemoglobin gm/dl 7.23 0.007 0.759 9.11 0.003 0.679
Iron mcg/dl 0.60 NS 0.60 NS
Lactate dehydrogenase U/liter 2.63 NS 2.98 0.084 1.004
Phosphorus mg/dl 0.78 NS 0.91 NS
Potassium meq/l 1.03 NS 0.68 NS
Pre-albumin mg/dl 13.57 ,0.001 0.929 9.79 0.002 0.925
Total iron binding capacity mcg/dl 4.28 0.039 0.994 4.09 0.043 0.992
Iron binding capacity sat. % ,0.01 NS ,0.01 NS
Alkaline phosphatase U/liter 0.03 NS
ALT U/liter 1.61 NS
AST U/liter 0.61 NS
Lymphocyte count 103/ml 10.10 0.002 0.926
Neutrophil count 103/ml 8.06 0.005 1.053
Platelet count 103/ml 5.76 0.016 1.004
Reticulocyte count % 0.03 NS
Variables are: x2, Chi-square statistic; P, probability of Ho (NS means not significant to reject @ P # 0.10); OR, odds ratio of death for the variable
if P # 0.10.
Variables were estimated before the first step of a forward, stepwise, logistic regression process. Death risk was evaluated over the subsequent 6
months from the initial date of data retrieval.
Table 3. Logistic regression model of death risk using adjusted
demographic and primary laboratory variablesa
Variable x2 P OR 95% CL
Albumin g/dl 13.2 ,0.001 0.29 0.15–0.56
Creatinine mg/dl 12.8 ,0.001 0.83 0.75–0.92
Phosphorous mg/dl 7.5 0.006 1.24 1.06–1.44
Gender (ref 5 male) 2.7 0.099 0.62 0.35–1.10
a See Table 2 for a list of variables evaluated by this model. Variables
are listed in order of entry into the model. Death risk was evaluated over
the subsequent 6 months from the initial date of data retreival. x2 means
the Chi-square statistic; P means probability of Ho; OR means the odds
ratio for death; 95% CL means the 95% confidence limit of the OR.
Table 4. Logistic regression model of death risk using adjusted
demographic and primary and extended laboratory variablesa
Variable x2 P OR 95% CL
Albumin 5.7 .017 0.34 0.14–0.83
Creatinine 6.0 .014 0.85 0.75–0.97
Lymphocyte count 4.3 .038 0.95 0.90–1.00
Phosphorous 5.5 .019 1.26 1.04–1.52
a See Table 2 for a list of variables evaluated by this model. Variables
are listed in order of entry into the model. Death risk was evaluated over
the subsequent 6 months from the initial date of data retreival. x2 means
the Chi-square statistic; P means probability of Ho; OR means the odds
ratio for death; 95% CL means the 95% confidence limit of the OR.
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Substituting a Cox model analysis of the primary vari-
ables, which included censored patients, yielded results
similar to the logistic analysis that did not include censored
patients. The concentrations of serum albumin, creatinine,
and phosphorus were identified as significantly associated
with death risk, but gender was not. A similar analysis of
primary plus extended laboratory variables revealed creat-
inine, hemoglobin, lymphocyte count, phosphorus, and
gender to be associated with death risk in the final model.
Because the serum albumin concentration strongly corre-
lated with death risk alone, it was selected for inclusion at
the first step. However, the combined and direct correla-
tion of death risk with creatinine, lymphocyte count, and
hemoglobin contributed to the elimination of the albumin
concentration.
DISCUSSION
Detecting the associations that link complicated data
elements and then translating the links into meaningful
pathobiological dimensions can be a difficult task. This
dilemma is particularly true when there is a network of
associations between the data elements. The ultimate in-
tent of such analyses is to discover how the clinical and
laboratory variables are associated with important outcome
measures of clinical care. A fundamental outcome measure
that is influenced by the processes of patient care is the
odds of survival on hemodialysis. Because it is impossible to
internally or externally monitor the processes of clinical
care in a direct manner, clinicians and regulators must rely
upon laboratory surrogates of these operations. Using a
large and representative, national database of hemodialysis
patients, we examined the statistical interactions between
laboratory variables and dialysis patient mortality. Al-
though some of the r values reported herein are relatively
low, suggesting that some of the variability in the test being
scrutinized was accounted for by factors other than those
being analyzed, the very low P values make it mathemati-
cally unlikely that the associations are random interactions.
Considering that this was an uncontrolled, observational
analysis of hemodialysis patients, in which uniformity of
disease processes and their management was absent, the
clinical relationships described by these r values are of
intellectual significance and clinically relevant.
The logistic regression analysis described a strong, inde-
pendent, inverse relationships between the serum albumin
and creatinine concentrations and the odds risk of death,
but no such relationship for CRP. These observations are
similar to earlier findings and suggest an inverse association
between the body’s content of both visceral and somatic
proteins and odds of death [2, 5–8, 13, 33]. These labora-
tory measures are highly correlated, and their independent
associations with odds of death suggests that the adequacy
of the body’s content of protein is strongly associated with
the patient’s likelihood of long-term survival [6, 7]. The
proinflammatory and catabolic cytokines that stimulate the
production of CRP also cause muscle catabolism with the
liberation of amino acids and inhibition of muscle protein
synthesis [22–26]. Furthermore, these cytokines may induce
anorexia, so further compromise protein stores through
diminished protein/caloric intake. Hence, one nexus be-
tween inflammation and visceral/somatic protein content
among dialysis patients includes the cytokine-mediated
acute phase processes.
In contrast to a previous report [34], the current analysis
did not find CRP to be an independent predictor of survival
for ESRD patients. Critical differences include the inclu-
sion of a far greater number of subjects, the use of a more
extensive laboratory profile, and the analysis of outcomes
among ambulatory ESRD patients instead of hospitalized
subjects for the present analysis. The current database does
not permit extrapolation of these results to patients who
are more ill and hospitalized, and vice versa. Because of its
more rapid induction and shorter half-life, CRP may be a
more dynamic marker of short-term inflammation/injury
than the serum albumin or creatinine concentration. An
alternative explanation for the observed difference in the
predictive power of CRP is that proximate mortality may be
better reflected by CRP, whereas longer term patient
survival may be predicted by the alternative laboratory
surrogates of nutrition. Circumspect extrapolation of CRP
as an independent outcome predictor for the hemodialysis
patient population is urged.
Similarly, the data presented herein support and extend
the hypothesis that a low serum albumin concentration may
not simply reflect inadequate intake of dietary protein
and/or calories. Depleted stores of vital proteins may result
in part from down-regulation of protein synthetic processes
and up-regulation of catabolic processes. For example, the
in vitro treatment of hepatocytes with IL-1b rapidly inhibits
albumin synthesis [35]. Furthermore, a dietary and kinetic
observational analysis of hypoalbuminemic ESRD patients
revealed that some subjects had appropriate protein/caloric
intakes, normalized protein catabolic rates, low dialysate
albumin losses, and diminished albumin turnover rates [36].
For these patients, the degree of hypoalbuminemia corre-
lated with the elevation of serum levels of laboratory
surrogates of inflammation, such as the CRP, a2-macro-
globulin, ferritin, and serum amyloid A concentration [36,
37]. These studies suggest that in some hypoalbuminemic
ESRD patients, cytokine-mediated inflammation induces
hypoalbuminemia.
Multiple regression analyses revealed independent asso-
ciations of visceral protein measures and CRP with blood
hemoglobin concentration. These findings suggests that
anemia is also associated with both cytokine-dependent
inflammation and nutritional status. The direct association
of CRP with rhEPO dose, and its inverse association with
albumin, support this linkage. Further independent support
for this hypothesis is provided by the observation that
ESRD patients with elevated blood levels of interleukin
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(IL)-6 are more anemic, and this anemia is corrected by
reducing the cytokine levels [38]. Similarly, nude mice
transfected with tumor necrosis factor (TNF) develop
severe anemia [39]. The observed iron indices in this
patient base also supports the provocative role of proin-
flammatory cytokines linking erythropoiesis and nutrition.
We observed that the serum iron, TIBC, and Sat-IBC
tended to be normal to low, but the ferritin was high. This
laboratory pattern has been observed for other ESRD
patient bases [40, 41]. In a recent analysis, .50% of the
patients had IBC saturation ,20%, and 44% of the pa-
tients had serum ferritin concentration .200 mg/liter [42].
This pattern of alteration for iron indices is commonly seen
in the anemia accompanying chronic disease (ACD) [43,
44]. Hematologic indices of ACD have been observed
during states of elevated cytokine activity [44].
We also observed an inverse statistical relationship be-
tween seemingly disparate processes, like nutritional status
and anemia. Similar findings have been reported by others
[41, 45]. In those earlier analyses, the serum albumin
concentration was the most powerful predictor of anemia
among the laboratory measures evaluated. Clinical support
for this statistical link is provided by the longitudinal
observation of the serum albumin and hemoglobin concen-
trations in malnourished ESRD patients receiving intradia-
lytic parenteral nutrition (IDPN) [13, 46]. During the six
months of observation prior to receiving IDPN, the decline
in serum albumin concentration was accompanied by a
parallel decrease in hemoglobin concentration, despite
increasing rhEPO doses. After the initiation of IDPN, the
patients’ albumin and hemoglobin concentrations in-
creased, and their odds risk of death declined [13]. Further
support for this linkage is provided by the observation that
severely malnourished patients without renal disease de-
velop anemia that is reversed by correction of protein/
caloric malnutrition alone [47, 48]. Arguably, a cytokine-
dependent decline in nutritional status may further impair
erythropoiesis in some malnourished patients [19].
In the current analysis, C-reactive protein was inversely
associated with laboratory measures of protein stores (al-
bumin, creatinine, prealbumin). CRP is an archetypal acute
phase reactant, so called because of increased blood levels
with acute inflammatory processes [20, 22–26]. Like fer-
ritin, the hepatic synthesis of CRP is augmented by proin-
flammatory cytokines, such as IL-1b and TNF-a. The
hepatic synthesis of albumin, prealbumin, and transferrin,
are reciprocally inhibited by those cytokines [22–24].
Hence, a biochemical explanation exists for the observed
pattern of statistical associations and that provides a com-
mon pathobiology shared for anorexia, depletion of vital
body proteins, laboratory signs of inflammation, and dial-
ysis-associated anemia. The common pathobiologic feature
is the presence of proinflammatory cytokines, either alone
or in combination with a diminished protein-caloric intake,
effecting deleterious changes in multiple physiologic sys-
tems.
Lastly, death risk was higher in patients with a low
lymphocyte count, an observation also made in other
patients during the course of malnutrition [49, 50]. The
fundamental role of lymphocytes in the effector limb of
adaptive immunity suggests that lymphopenia may increase
infectious risk in this population. The observation of a
lymphocyte effect on death risk, that is independent of
nutritional surrogates like albumin, suggests that deleteri-
ous immunologic dysfunction can also occur in this popu-
lation in the absence of overt laboratory signs of malnutri-
tion. A fundamental unanswered question is what is the
proximate cause of the death in these situations: is it the
inciting process(es) resulting in the excesses of proinflam-
matory cytokine(s), and/or is mortality a consequence of
the deleterious pathobiologic effects of the cytokines on
nutrition, hematopoiesis, etc.? If a particular pathobiologic
process links seemingly disparate processes, such as anemia
and the depletion of visceral body proteins, the question is
raised whether it is the process, its provocateur, or the
consequences of the depletion that is most closely associ-
ated with mortal risk. Both albumin and creatinine concen-
trations are closely associated with the odds of death in
these and other studies [2, 5, 7, 8, 33,], whereas CRP is not.
Differences in statistical linkages between the logistic
regression model and Cox proportional hazard model were
observed and are unsurprising. There is no a priori reason
that identical results should be achieved with the two
models. Although both models examine the statistical
impact of clinical variables on mortality, their conceptual
construct of death risk is quite different. A logistic regres-
sion model determines the odds risk of survival, whereas
the Cox model assesses variables that effect the length of
survival. Because these two models conceptually view pa-
tient mortality in different, but complimentary ways, they
were used to support the observation about CRP, not to
achieve statistical uniformity. Thus, the data presented
herein offer additional support for the hypothesis that a
major contributor to mortal risk in ESRD is the depletion
of body proteins, not inflammation.
Because laboratory surrogates of nutrition, such as the
albumin and creatinine concentration are influenced to
varying degrees by processes other than protein/caloric
intake and nutrient utilization, the statistical linkages de-
scribed herein should be extended by correlation with more
direct measures of patients’ nutritional status, such as
bioelectrical impedance and dual energy x-ray absorptiom-
etry [51].
Reprint requests to William F. Owen, Jr., M.D., Brigham and Women’s
Hospital, Dialysis Unit Administrative Office, 75 Francis Street, Boston,
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